The observation of prominent neoangiogenesis and high expression levels of VEGF in GBM of elderly patients provides a rationale for the symptomatic use of bevacizumab, a monoclonal anti-VEGF antibody [45, 46]. This evidence concerns the gene VEGFA and glioblastoma.